Australia TGA ARTG recordOphteisBio 1.8% - Aqueous/vitreous humour replacement medium
Australia TGA ARTG Registered Device · Kevin Grundy (IBD) Pty Ltd · Rayner Intraocular Lenses Ltd · Class III · Started November 14, 2023
Good Name: Kevin Grundy (IBD) Pty Ltd - OphteisBio 1.8% - Aqueous/vitreous humour replacement medium
- Risk Class
- Class III
- Product Type
- Procedure Pack
- ARTG Category
- General
- Start Date
- November 14, 2023
- Effective Date
- November 14, 2023
- Country
- United Kingdom
- Address
- The Ridley Innovation Centre 10 Dominion Way, Worthing, West Sussex, BN14 8AQ
Indicated for use in intraocular surgery of the anterior segment, including cataract extraction and intraocular lens implantation. The viscoelastic properties of OphteisBio 1.8% allow lubrication, support and protection of ocular tissues during ophthalmic surgery. Maintains the depth of the anterior chamber during surgery, allows for efficient manipulation with reduced trauma to the corneal endothelium and other surrounding tissues.
Access comprehensive regulatory information for OphteisBio 1.8% - Aqueous/vitreous humour replacement medium in the Australia medical device market through Pure Global AI's free TGA ARTG database. This Class III is sponsored by Kevin Grundy (IBD) Pty Ltd, manufactured by Rayner Intraocular Lenses Ltd in United Kingdom. The device registration started on November 14, 2023.
This page provides complete registration details including sponsor information, manufacturer details, and regulatory compliance data from the official Australia TGA ARTG medical device database. Pure Global AI offers free access to Australia's complete medical device registry with 131,000+ devices, helping global MedTech companies navigate TGA regulations efficiently.